The estimated Net Worth of John A. Borgeson is at least $7.43 million dollars as of 15 June 2024. Mr. Borgeson owns over 5,494 units of Kodiak Sciences Inc stock worth over $457,044 and over the last 5 years he sold KOD stock worth over $751,508. In addition, he makes $6,223,180 as Chief Financial Officer, Senior Vice President et Secretary at Kodiak Sciences Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Borgeson KOD stock SEC Form 4 insiders trading
John has made over 10 trades of the Kodiak Sciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,494 units of KOD stock worth $13,570 on 15 June 2024.
The largest trade he's ever made was exercising 5,494 units of Kodiak Sciences Inc stock on 15 June 2024 worth over $13,570. On average, John trades about 2,115 units every 66 days since 2019. As of 15 June 2024 he still owns at least 185,038 units of Kodiak Sciences Inc stock.
You can see the complete history of Mr. Borgeson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Borgeson biography
John A. Borgeson is Chief Financial Officer, Senior Vice President, Secretary of the company since January 2016. Mr. Borgeson is our Senior Vice President, Chief Financial Officer and Secretary and has served in this position since January 2016. Mr. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. From January 2013 until December 2015, Mr. Borgeson led finance for a variety of private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals. Previously, Mr. Borgeson was a Vice President of Finance at Pfizer Inc. and a member of Pfizer’s Global Finance and Business Operations Leadership Team. Mr. Borgeson’s roles at Pfizer included finance head for Pfizer’s biotherapeutics and bioinnovation group and corporate tax executive with responsibility for the United States and Europe. Mr. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant (inactive). He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
What is the salary of John Borgeson?
As the Chief Financial Officer, Senior Vice President et Secretary of Kodiak Sciences Inc, the total compensation of John Borgeson at Kodiak Sciences Inc is $6,223,180. There are 2 executives at Kodiak Sciences Inc getting paid more, with Victor Perlroth having the highest compensation of $17,642,000.
How old is John Borgeson?
John Borgeson is 58, he's been the Chief Financial Officer, Senior Vice President et Secretary of Kodiak Sciences Inc since 2016. There are 5 older and 7 younger executives at Kodiak Sciences Inc. The oldest executive at Kodiak Sciences Inc is Robert Profusek, 70, who is the Lead Independent Director.
Insiders trading at Kodiak Sciences Inc
Over the last 6 years, insiders at Kodiak Sciences Inc have traded over $15,919,920 worth of Kodiak Sciences Inc stock and bought 10,439,459 units worth $472,964,631 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bros. Advisors Lp667, L.P.B... et Victor Perlroth. On average, Kodiak Sciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $393,170. The most recent stock trade was executed by John A. Borgeson on 15 June 2024, trading 5,494 units of KOD stock currently worth $13,570.
What does Kodiak Sciences Inc do?
about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
What does Kodiak Sciences Inc's logo look like?
Complete history of Mr. Borgeson stock trades at Kodiak Sciences Inc
Kodiak Sciences Inc executives and stock owners
Kodiak Sciences Inc executives and other stock owners filed with the SEC include:
-
Victor Perlroth,
Chairman of the Board, President, Chief Executive Officer -
Jason Ehrlich,
Chief Medical Officer and Chief Development Officer -
John Borgeson,
Chief Financial Officer, Senior Vice President, Secretary -
Dr. Victor Perlroth M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Jason S. Ehrlich M.D., Ph.D.,
Chief Medical Officer & Chief Devel. Officer -
John A. Borgeson CPA, M.B.A., MBA, CPA,
Sr. VP, CFO & Sec. -
Taiyin Yang,
Independent Director -
Robert Profusek,
Lead Independent Director -
Bassil Dahiyat,
Independent Director -
Richard Levy,
Independent Director -
Felix Baker,
Independent Director -
Charles Bancroft,
Independent Director -
Almas Qudrat M.Sc.,
Sr. VP of Quality Operations -
Dr. Hong Liang,
Sr. VP of Discovery Medicine -
Hong Liang,
See Remarks -
Bros. Advisors Lp667, L.P.B...,